Condition: Advanced Solid Tumor · Sponsor: BioNTech SE
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| Norton Cancer Institute PARENT | Louisville, Kentucky, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Carolina BioOncology Institute, LLC | Huntersville, North Carolina, United States | Recruiting |
| Rhode Island Hospital | East Providence, Rhode Island, United States | Recruiting |
| MUSC Hollings Cancer Center | Charleston, South Carolina, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| South Texas Accelerated Research Therapeutics (START), LLC | San Antonio, Texas, United States | Recruiting |
| Tasman Oncology Research Ltd | Southport, Queensland, Australia | Recruiting |
| Cancer Research SA | Adelaide, Australia | Recruiting |
| Monash Medical Centre Clayton | Clayton, Australia | Recruiting |
| Scientia Clinical Research | Randwick, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06750185